Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.
作者信息
Whittington Melanie D, McQueen R Brett, Campbell Jonathan D
机构信息
Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
出版信息
JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049.
Abstract
摘要
相似文献
1
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.儿科治疗性疗法成本效益分析的考量因素
JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049.
2
Rollout of high-priced cell and gene therapies forces payer rethink.高价细胞和基因疗法的推出迫使支付方重新思考。
Nat Biotechnol. 2018 Apr 5;36(4):291-292. doi: 10.1038/nbt0418-291a.
3
The high price of progress.进步的高昂代价。
Nat Rev Clin Oncol. 2017 Feb 20;14(3):129. doi: 10.1038/nrclinonc.2017.24.
4
Balancing patient value and payer cost in hematologic malignancies: can it be done?在血液系统恶性肿瘤中平衡患者价值与支付方成本：这能做到吗？
Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13.
5
Approvals in 2016: questioning the clinical benefit of anticancer therapies.2016年的批准情况：质疑抗癌疗法的临床益处。
Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.
6
Kymriah: A Sign of More Difficult Decisions To Come.基姆瑞亚（Kymriah）：未来更艰难决策的一个信号。
Manag Care. 2018 May;27(5):17.
7
Approvals in 2016: cost-benefit challenges of new anticancer agents.2016年的批准情况：新型抗癌药物的成本效益挑战
Nat Rev Clin Oncol. 2017 Feb 20;14(3):133-134. doi: 10.1038/nrclinonc.2017.12.
8
CAR T-cell therapy: perceived need versus actual evidence.嵌合抗原受体T细胞疗法：感知到的需求与实际证据
Lancet Oncol. 2018 Oct;19(10):1259. doi: 10.1016/S1470-2045(18)30698-3. Epub 2018 Oct 1.
9
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.1965年至2016年美国食品药品监督管理局批准时癌症药物的月度成本和中位数成本。
J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173.
10
Being NICE is not the problem!友善并不是问题！
Eur J Cancer. 2009 May;45(7):1100-1102. doi: 10.1016/j.ejca.2009.01.035. Epub 2009 Mar 4.
引用本文的文献
1
Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein.应用血清甲胎蛋白对极低出生体重儿进行肝母细胞瘤筛查的成本效果分析。
J Pediatr. 2020 Oct;225:80-89.e4. doi: 10.1016/j.jpeds.2020.05.041. Epub 2020 May 26.
2
Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.抗 CD19 嵌合抗原受体 T 细胞疗法治疗儿童复发/难治性 B 细胞急性淋巴细胞白血病的成本效益。一种社会观点。
Eur J Haematol. 2020 Aug;105(2):203-215. doi: 10.1111/ejh.13427. Epub 2020 May 4.
3
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.嵌合抗原受体 T 细胞疗法治疗复发或难治性儿童白血病患者的长期生存和价值。
JAMA Pediatr. 2018 Dec 1;172(12):1161-1168. doi: 10.1001/jamapediatrics.2018.2530.
Zotero 插件